Navigation Links
Dragon Sells EPO Business; Focus on Antibiotic Core Business
Date:11/14/2007

VANCOUVER, Nov. 14 /PRNewswire-FirstCall/ - Dragon Pharmaceutical Inc. (TSX: DDD; OTCBB: DRUG; BBSE: DRP) today announced that it has entered an agreement with an unaffiliated party for the sale of its EPO business which accounted for less than 3% of Dragon's consolidated revenue for the first nine months of 2007. The decision was made based on the studies of the EPO market which showed limited growth potential, if not downward trend, during the next three years. The Company considers this decision an important part of Dragon's ongoing strategy to fully focus on its core business of antibiotic product lines that have shown tremendous growth over the past years.

Over the past three years, Dragon's revenues from antibiotic products increased from $31.23 million for the year of 2005 to approximately $60 million for the first nine months of 2007, reflecting the strong market demand as well as enhanced competitiveness of the Company in antibiotic products. Mainly due to the strong growth of antibiotic products, EPO business only accounted for less than 3% of total revenues for the first nine months of 2007, as compared to 11% of the total revenues for the year of 2005. Since EPO business is no longer a significant and growing component of our product portfolio, the Company decided that it is in the best interests of its shareholders to sell its EPO business and concentrate all its resources on the antibiotic product lines which offered the greatest growth potential.

According to the agreement, the EPO business will be sold for $2.08 million. The transaction is expected to be completed during the fourth quarter of 2007. Because of this disposal, the Company recorded a non-cash impairment charge of $2.64 million during the current quarter related to the write down of the intangible assets and goodwill associated with the Biotech division which was created as a result of the reverse take-over of Dragon Pharmaceutical Inc. by Oriental Wave Holdings Limited on January 12, 2005. During the three and nine months ended September 30, 2007, the Company recognized $0.97 million and $2.12 million after-tax income from continuing operations.

"Our EPO business performed well during the past years. However, an in-depth review of the EPO business has concluded that it is very demanding in market resources but with very limited growth potential," said Mr. Yanlin Han, Chairman and CEO of the Company. "We are focusing our efforts in the antibiotic market which we intend to lead while showing a sustainable and growing profit. In addition, the Company is also actively exploring additional business opportunities in broadening its core antibiotic product offerings and increasing production capacities. We are confident that the benefits of all these initiatives will be reflected in the Company's performance in the future."

This press release contains forward looking statements such as the Company's Chemical and formulation business to be competitive and successful in the marketplace. These statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward looking statements. Readers should not place undue reliance on forward looking statements, which only reflect the view of management as of the date hereof. The Company does not undertake the obligation to publicly revise these forward looking statements to reflect subsequent events or circumstances. Readers should carefully review the risk factors and other factors described in its periodic reports with the Securities and Exchange Commission.

CONTACT: Dragon Pharmaceutical Inc.: Maggie Deng, Telephone: (604) 669-8817 or North America Toll Free: 1-877-388-3784, Email: irdragon@dragonpharma.com, Website: http://www.dragonpharma.com


'/>"/>
SOURCE Dragon Pharmaceutical Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Dragon Achieved Solid Increase in Sales and Profits from Continuing Operations for Q3
2. Celebrity Seating Only! Levitz Chair Signed by 39 Daytime Stars Sells for $1200 on Charitybuzz.com
3. NPS Sells Assets Related to mGluR Collaboration to AstraZeneca for $30 Million to Support Late-Stage Product Development
4. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
5. Academy of General Dentistry Launches Campaign to Focus on Tooth Erosion
6. Education Key Focus of Michigan Policy Summit
7. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
8. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
9. This October, the American Physical Therapy Associations National Physical Therapy Month to Focus on Nations Obesity Epidemic
10. DuPont Focused on Meeting Global Demands for Greater Safety & Protection
11. New Seminar Series from Activator Methods Teaches Doctors a Unique Approach to Improving Nations Chiropractic Care: Focus on the Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Woodinville, WA (PRWEB) , ... May 05, 2016 ... ... better user experience, adapted to people’s every day living patterns, Amerec, a Seattle-based ... easy-to-use computer and smart phone app. , The user interface of the app, ...
(Date:5/5/2016)... ... 2016 , ... United Collection Bureau, Inc. (UCB) announces Sarah Clark as its ... of experience within the healthcare revenue cycle industry. With a primary focus of end-to-end ... Financial Services at Spectrum Health. While at Spectrum Health, Clark helped Spectrum achieve the ...
(Date:5/5/2016)... ... May 05, 2016 , ... CURE Media Group , the nation’s ... new collaboration with Imerman Angels to expand outreach and emotional support for ... “Imerman Angels provides an emotional lifeline to patients and families facing the challenges of ...
(Date:5/5/2016)... ... May 05, 2016 , ... Pigment Laser Tattoo Removal Center ... technology of the new PiQo4™ laser, the first 4-wavelenth picosecond laser to receive FDA ... any other picosecond laser on the market. Jeremy Miller, Tattoo Artist and former ...
(Date:5/5/2016)... ... ... Nepenthe Laboratory Services (NLS), a premier drug monitoring and toxicology laboratory, held ... donations for Food for Lane County, and to help support awareness for the upcoming ... assembly was to create an exciting atmosphere for the kids at Riverbend to aspire ...
Breaking Medicine News(10 mins):
(Date:5/3/2016)... 3, 2016 BioNovus Innovations LLC and ... Advancing Medical Innovation (IAMI) today announced a new ... and medical devices. An agreement between ... to license, develop and commercialize medical innovations advanced ... "This partnership represents a significant advance in our ...
(Date:5/3/2016)... 2016  As a teenager, an active and athletic ... damaged his heart. He continued enjoying sports and recreation ... Shepherd,s heart was giving out and he was a ... 2013, the Mesa, Arizona resident ... a heart transplant, the SynCardia TAH-t is the only ...
(Date:5/3/2016)... ORANGE COUNTY, Calif. , May 3, 2016  While you may be familiar with watching ... 4K resolution , also known as ultra-high-definition or 8MP in the Medical Industry.  Ampronix  is ... class manufacturer of innovative technology. Photo - http://photos.prnewswire.com/prnh/20160502/362730 ... ... ...
Breaking Medicine Technology: